Latest Headlines

Latest Headlines

Indonesia's Indofarma combines its manufacturing expertise with Kimia's supply chain strength

Indonesia is one of those emerging markets that has pressured outside companies to produce locally and companies like Pfizer, Merck and Fresenius Kabi have all built or expanded plants there in recent years. But the government, which controls some of the players, is taking steps to improve efficiency in the domestic market, pushing for a merger that ties the manufacturing expertise of one company to the supply chain strength of another.

GSK buys full control of consumer unit in Indonesia

Indonesia is one of the rapidly growing markets that drugmakers are trying to tap to boost sales, and GlaxoSmithKline is upping its bet. The U.K.-based drugmaker said today it will buy full control of its consumer health unit there.

Pfizer is expanding its plant in Indonesia--again

Pfizer, which boosted production at its plant in Indonesia in 2012, is expanding there again.

Fresenius carving out its piece of expanding Indonesian drug market

The generics division of the German healthcare company has bought controlling interest in Indonesian drugmaker PT Ethica Industri Farmasi from PT Soho Global Healthcare. The two will build a $60 million plant to make IV generic drugs and infusion solutions and make Fresenius Kabi the market leader in IV generics in Indonesia.

Fresenius Kabi expands manufacturing in Indonesia with JV

Germany's Fresenius Kabi has decided to expand into Southeast Asia with a plant in Indonesia to make intravenous drugs, buying controlling interest in Indonesian drugmaker PT Ethica Industri Farmasi from PT Soho Global Healthcare.

Fresenius inks deal for 51% stake in Indonesian drugmaker

Sources tell The Wall Street Journal that the deal could be worth $200 million.

Vietnam drug spending makes it a prime pharma target

Last year Sanofi boss Chris Viehbacher ran out his list of his favorite emerging market opportunities including Colombia, Indonesia and Vietnam. A new rundown on recent developments in Vietnam, show the many reasons why Viehbacher would see the southeast Asian country as a very good bet.

Quintiles eyes first global trial for Indonesia

While Quintiles has been active in Indonesia since 2006, it has never been able to involve the country in a global clinical trial. That's all changing thanks to a partnership with Indonesia's Prodia Clinical Laboratory.

Indonesia invites cheap copies of 7 patented HIV drugs

Asia is becoming a danger zone for pharma's intellectual property. On the heels of India's first compulsory licensing move, Indonesia has nixed patent protection on 7 HIV fighters and hepatitis drugs. The move would open the gates to cheap generic rivals, expanding access--and cutting into sales of pharma's brand names.

Merck opens $21M Jakarta packaging plant

Merck ($MRK) has opened a $21 million packaging plant in Indonesia, expecting to tap growth in Asian markets.